Glen Johnson, MD
Psychiatry · West Valley City, UTNPI 1326157298
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Vanda Pharmaceuticals Inc. at 24.3% of the total. Reporting peaked in 2020 at $340 and has fallen 90.1% since, to $34 in 2025.
Across 84 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$341
- Neurocrine Biosciences, Inc.$189
- AbbVie$180
- Teva Pharmaceuticals USA, Inc.$153
- Johnson & Johnson$139
- Jazz Pharmaceuticals Inc.$123
- plus $277 from 9 others
What the payments were for
- Food & beverage$1,396100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 20 | $341 |
| Neurocrine Biosciences, Inc. | 9 | $189 |
| AbbVie(2 entities) | 10 | $180 |
| Teva Pharmaceuticals USA, Inc. | 9 | $153 |
| Johnson & Johnson | 9 | $139 |
| Jazz Pharmaceuticals Inc. | 8 | $123 |
| Eisai Inc. | 5 | $69 |
| Almatica Pharma LLC | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Lundbeck LLC | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Merck | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,402 in reported general payments places this provider in the 85th percentile of 231 psychiatry providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 16 | $121,742 |
| FetzimaLevomilnacipran Hcl | 20 | $9,473 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 119 | $4,713 |
| Quetiapine Fumarate | 208 | $4,307 |
| Clonazepam | 252 | $3,558 |
| Alprazolam | 428 | $3,197 |
| Trazodone Hcl | 235 | $3,166 |
| Oxcarbazepine | 71 | $2,911 |
| Alprazolam OdtAlprazolam | 13 | $2,750 |
| Bupropion Hcl SrBupropion Hcl | 175 | $2,729 |
| Clozapine | 23 | $2,646 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $2,026 |
| Bupropion XlBupropion Hcl | 56 | $1,821 |
| Atomoxetine Hcl | 24 | $1,798 |
| Aripiprazole | 28 | $1,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $189 | $121,74216 claims |
| AbbVieFetzima | $180 | $9,47320 claims |
| Almatica Pharma LLCSertraline Hcl | $53 | $44636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 231 psychiatry providers in Utah.
Other psychiatry in West Valley City
- Michael MeasomSlc$2.2M
- Noel GardnerSalt Lake City$512K
- Reid RobisonOrem$133K
- Thomas RaynerProvo$60K
- Trent HolmbergDraper$32K
- Nathan CurrierRiverton$21K
- Oliver McPhersonBountiful$20K
- Frederick ReimherrSalt Lake City$18K
- Lisa FraleighLogan$8K
- Clark JohnsonSalt Lake City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.